*3.4.8. Dasatinib*

Dasatinib is another second-generation TKI with activity against BCR-ABL and Src family kinases that is approved for the treatment of imatinib-resistant Ph-positive CML and Phpositive acute lymphoblastic leukemia [145]. In a retrospective survey on patients with Phpositive CML who received dasatinib, 5 (50%) patients had TFT abnormalities consistent with hypothyroidism (4 subclinical, 1 clinical) and 2 patients (20%) had thyroid values consistent with subclinical hyperthyroidism. No patient required LT4, except one patient who developed hypothyroidism and was also taking amiodarone, a medication known to cause thyroid dysfunction. Two patients were on LT4 prior to starting dasatinib and modification of LT4 was not required [143].
